Isotretinoin 5 mg daily for low-grade adult acne vulgaris - A placebo-controlled, randomized double-blind study

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 6, 2014, Pages 747-754

  Rademaker, M ^a   Wishart, J M ^b   Birchall, N M ^c  

^a WAIKATO HOSPITAL   (New Zealand)

^b Auckland Dermatology ^*  (New Zealand)

^c Auckland Dermatology   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EMOLLIENT AGENT; GAMMA GLUTAMYLTRANSFERASE; ISOTRETINOIN; PLACEBO; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ACTINIC CHEILITIS; ARTICLE; CHEILITIS; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY LIP; DRY SKIN; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MOOD CHANGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; SIDE EFFECT; TREATMENT DURATION; ADULT; DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ACNE VULGARIS; ADULT; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX;

EID: 84900394258     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12170     Document Type: Article

References (33)

1. Goulden V, Stables GI, Cunliffe WJ,. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41: 577-580.
2. Cunliffe WJ, Gould DJ,. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J 1979; 1: 1109-1110.
3. Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB,. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt) 2012; 21: 223-230.
4. Poli F, Dreno B, Verschoore M,. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15: 541-545.
5. Collier CN, Harper JC, Cafardi JA, et al,. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56-59.
6. Choi CW, Lee DH, Kim HS, Kim BY, Park KC, Youn SW,. The clinical features of late onset acne compared with early onset acne in women. J Eur Acad Dermatol Venereol 2011; 25: 454-461.
7. Capitanio B, Sinagra JL, Bordignon V, Cordiali Fei P, Picardo M, Zouboulis CC,. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol 2010; 63: 782-788.
8. Gollnick HP, Finlay AY, Shear N,. Global alliance to improve outcomes in acne. Can we define acne as a chronic disease? If so, how and when?. Am J Clin Dermatol 2008; 9: 279-284.
9. Thiboutot DM, Lookingbill DP,. Acne: acute or chronic disease? J Am Acad Dermatol 1995; 32: S2-S5.
10. Williams C, Layton AM,. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol 2006; 7: 281-290.
11. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al,. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351-357.
12. Geissler SE, Michelsen S, Plewig G,. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 2003; 1: 952-958.
13. Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G,. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 2003; 23: 41-46.
14. Plewig G, Dressel H, Pfleger M, Michelsen S, Kligman AM,. Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne. J Dtsch Dermatol Ges 2004; 2: 31-45.
15. Amichai B, Shemer A, Grunwald MH,. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 644-646.
16. Rademaker M,. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010; 51: 248-253.
17. Burke BM, Cunliffe WJ,. The assessment of acne vulgaris-the Leeds technique. Br J Dermatol 1984; 111: 83-89.
18. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
19. Shaw JC, White LE,. Persistent acne in adult women. Arch Dermatol 2001; 137: 1252-1253.
20. Dreno B, Castell A, Tsankov N, et al,. Interest of the association retinaldehyde/glycolic acid in adult acne. J Eur Acad Dermatol Venereol 2009; 23: 529-532.
21. McConnell RC, Fleischer AB Jr, Williford PM, Feldman SR,. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: an analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol 1998; 38: 221-226.
22. Seukeran DC, Cunliffe WJ,. Acne vulgaris in the elderly: the response to low-dose isotretinoin. Br J Dermatol 1998; 139: 99-101.
23. Goulden V, Clark SM, McGeown C, Cunliffe WJ,. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997; 137: 106-108.
24. Lee JW, Yoo KH, Park KY, et al,. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164: 1369-1375.
25. Palmer RA, Sidhu S, Goodwin PG,. 'Microdose' isotretinoin. Br J Dermatol 2000; 143: 205-206.
26. Thielitz A, Krautheim A, Gollnick H,. Update in retinoid therapy of acne. Dermatol Ther 2006; 19: 272-279.
27. Balmer JE, Blomhoff R,. Gene expression regulation by retinoic acid. J Lipid Res 2002; 43: 1773-1808.
28. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM,. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinology 2009; 1: 177-187.
29. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM,. Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol 2009; 129: 1038-1042.
30. Zouboulis CC, Korge BP, Mischke D, Orfanos CE,. Altered proliferation, synthetic activity, and differentiation of cultured human sebocytes in the absence of vitamin A and their modulation by synthetic retinoids. J Invest Dermatol 1993; 101: 628-633.
31. Rademaker M,. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?. Australas J Dermatol 2012; Sep 26. doi: 10.1111/j.1440-0960.2012.00947.x. [Epub ahead of print].
32. Layton AM, Dreno B, Gollnick HP, Zouboulis CC,. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773-776.
33. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D,. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205.